Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement.
Across FY2018–FY2025: $1.43B in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are senior unsecured obligations of Viatris. The Notes are guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. (the “Guarantors”).
Issuer evidence: On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are senior unsecured obligations of Viatris. The Notes are guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. (the “Guarantors”).
Supporting evidence: The Notes were issued pursuant to an Indenture (the “Base Indenture”), dated June 17, 2026, among the Company, the Guarantors and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), dated June 17, 2026, among the Company, the Guarantors and the Trustee (which includes the form of Notes as an exhibit). The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-287087). The Notes will accrue interest at a rate of 4.250% per annum, accruing from June 17, 2026, payable annually beginning June 17, 2027, and will mature on June 17, 2033, subject to earlier repurchase or redemption in accordance with the terms of the Indenture.
Supporting evidence: On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”).
On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the “Offering”) €650,000,000 principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are being offered pursuant to a Registration Statement on Form S-3 (File No. 333-287087), which became effective upon filing, and a Prospectus Supplement dated June 12, 2026, to a Prospectus dated May 8, 2025. The Offering is expected to close on June 17, 2026, subject to customary closing conditions.
Issuer evidence: On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the “Offering”) €650,000,000 principal amount of its 4.250% Senior Notes due 2033 (the “Notes”).
Supporting evidence: On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the “Offering”) €650,000,000 principal amount of its 4.250% Senior Notes due 2033 (the “Notes”).
Supporting evidence: On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the “Offering”) €650,000,000 principal amount of its 4.250% Senior Notes due 2033 (the “Notes”).
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.29×
Peer median 3.54×
EV/EBIT
—
Peer median 18.16×
P/E (TTM)
—
Peer median 21.98×
EV/Adj. EBITDA (TTM)
7.67×
Peer median 12.67×
Peer medians compare against the 18 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Developed Markets Segment
$8,552,100,000
$8,961,400,000
$9,278,000,000
$9,790,700,000
$10,428,700,000
$8,510,900,000
$8,240,000,000
$8,289,100,000
Greater China Segment
$2,332,500,000
$2,167,800,000
$2,160,400,000
$2,201,200,000
$2,212,800,000
$259,900,000
$214,600,000
$168,100,000
Emerging Markets Segment
$2,217,600,000
$2,260,400,000
$2,562,900,000
$2,637,000,000
$3,144,700,000
$1,853,800,000
$1,723,200,000
$1,678,700,000
Japan Australia and New Zealand Segment
$1,197,700,000
$1,349,700,000
$1,425,600,000
$1,633,800,000
$2,027,400,000
$1,195,300,000
$1,192,500,000
$1,132,800,000
By Geography (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
$3,006,700,000
$3,434,700,000
$3,551,800,000
$3,946,600,000
$4,176,400,000
$3,746,100,000
$3,965,900,000
$3,865,200,000
China
$2,079,800,000
$1,911,300,000
$1,889,000,000
$1,951,300,000
$1,981,500,000
$216,100,000
$171,100,000
—
France
—
—
—
—
—
$1,070,800,000
$1,047,600,000
$1,092,700,000
India
—
—
—
—
—
$1,155,400,000
$1,171,100,000
$1,164,800,000
By Product & Service (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Brands
$9,184,000,000
$9,200,300,000
$9,800,500,000
$9,889,600,000
$10,841,300,000
$5,234,900,000
$5,362,100,000
$5,523,700,000
Generics
$5,066,400,000
$5,492,500,000
$5,587,900,000
$6,328,500,000
$6,972,300,000
$5,289,500,000
$4,796,900,000
$5,222,400,000
Lipitor
$1,549,300,000
$1,468,800,000
$1,559,300,000
$1,635,200,000
$1,663,200,000
—
—
—
Norvasc
$709,900,000
$673,300,000
$732,400,000
$775,100,000
$824,700,000
—
—
—
Lyrica
$487,000,000
$495,400,000
$556,500,000
$623,800,000
$728,500,000
—
—
—
EpiPen Auto Injectors
$469,700,000
$392,000,000
$442,200,000
$378,000,000
$391,700,000
—
—
—
Viagra
$408,200,000
$395,600,000
$428,800,000
$458,900,000
$533,800,000
—
—
—
Creon
$365,800,000
$328,200,000
$304,900,000
$304,000,000
$309,800,000
—
—
—
Celebrex
$272,900,000
$285,600,000
$330,600,000
$338,100,000
$344,400,000
—
—
—
Yupelri
$266,900,000
$238,500,000
$220,800,000
$202,100,000
$161,900,000
—
—
—
Effexor
$257,700,000
$252,900,000
$262,900,000
$279,600,000
$316,800,000
—
—
—
Zoloft
$254,900,000
$235,700,000
$235,700,000
$246,200,000
$284,300,000
—
—
—
Influvac
$194,400,000
$178,700,000
$192,400,000
$225,500,000
$299,300,000
—
—
—
Dymista
$163,600,000
$188,000,000
$200,000,000
$179,800,000
$168,000,000
—
—
—
Xalabrands
$158,400,000
$166,400,000
$193,200,000
$195,100,000
$226,000,000
—
—
—
Amitiza
$158,100,000
$149,200,000
$157,000,000
$167,900,000
$201,500,000
—
—
—
Xanax
$139,900,000
$145,000,000
$154,800,000
$156,500,000
$185,900,000
—
—
—
Product And Service Other
—
—
—
—
—
$126,100,000
$130,200,000
$165,200,000
Product
—
—
$15,388,400,000
$16,218,100,000
$17,813,600,000
$11,819,900,000
$11,370,300,000
—
Complex GX and Biosimilars
—
—
—
$1,313,400,000
$1,342,100,000
$1,295,500,000
$1,211,300,000
$522,600,000
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
